Preparation of monoPEGylated human interferon beta-1a: Optimization of the conditions for N-terminal PEGylation

Applied Biochemistry and Microbiology

Volumn 51, Issue 7, 2015, Pages 774-785

  Korzhavin, D V ^a,b   Chernovskaya, T V ^a   Efanov, Yu G ^a   Rudenko, E G ^a   Ivanov, R A ^a   Pshenichnikova, A B ^b   Shvets, V I ^b  

^a BIOCAD Biopharmaceutical Company   (Russian Federation)

^b MIREA RUSSIAN TECHNOLOGICAL UNIVERSITY   (Russian Federation)

Author keywords

human IFN beta; modification; multiple sclerosis; polyethylene glycol; prolonged release form

Indexed keywords

EID: 84944687482     PISSN: 00036838     EISSN: None     Source Type: Journal    
DOI: 10.1134/S0003683815070030     Document Type: Article

References (22)

1. Zavalishin, I.A. and Peresedova, A.V., Multiple sclerosis: the modern concept of pathogenesis and pathogenetic treatment, Annaly Klinich. Eksp. Nevrol., 2007, no. 1, pp. 32–40.
2. Kappos, L., Weinshenker, B., Pozzilli, C., Thompson, A.J., Dahlke, F., Beckmann, K., Polman, C., and Mcfarland, H., Interferon beta-1b in secondary progressive ms: a combined analysis of the two trials, Neurology, 2004, vol. 63, no. 10, pp. 1779–1787.
3. Alam, J., Goelz, S., Rioux, P., Scaramucci, J., Jones, W., Mcallister, A., Campion, M., and Rogge, M., Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon beta-la (IFN beta-1a) products administered intramuscularly in healthy male and female volunteers, Pharmac. Res., 1997, vol. 14, pp. 546–549.
4. Bertolotto, A., Deisenhammer, F., Gallo, P., and Solberg Sorensen, P., Immunogenicity of interferon beta: differences among products, J. Neurology, 2004, vol. 251, no. 2, pp. 115–124.
5. Pasut, G. and Veronese, F.M., PEG conjugates in clinical development or use as anticancer agents: an overview, Adv. Drug Delivery Rev., 2009, vol. 61, no. 13, pp. 1177–1188.
6. Wong, S.S., Chemistry of Protein Conjugation and CrossLinking, CRC Press, 1991.
7. Zalipsky, S., Chemistry of polyethylene glycol conjugates with biologically active molecules, Adv. Drug Delivery Rev., 1995, vol. 16, nos. 2–3, pp. 157–182.
8. Kinstler, O., Molineux, G., Treuheit, M., Ladd, D., and Gegg, C., Mono-N-terminal poly(ethyelen glycol)-protein conjugates, Adav. Drug Delivery Rev., 2002, vol. 54, no. 4, pp. 477–485.
9. Roberts, M.J., Bentley, M.D., and Harris, J.M., Chemistry for peptide and protein PEGylation, Adv. Drug Delivery Rev, 2002, vol. 54, no. 4, pp. 459–476.
10. Runkel, L., Meier, W., Pepinsky, R.B., Karpusas, M., Whitty, A., Kimball, K., Brickelmaier, M., Muldowney, C., Jones, W., and Goelz, S.E., Structural and functional differences between glycosylated and nonglycosylated forms of human interferon-beta (IFNbeta), Pharm. Res., 1998, vol. 15, no. 4, pp. 641–649.
11. Baker, D.P., Pepinsky, R.B., Brickelmaier, M., Gronke, R.S., Hu, X., Olivier, K., Lerner, M., Miller, L., Crossman, M., Nesterov, I., Subraanyam, M., Hitchman, S., Glick, G., Richman, S., Liu, S., Zhu, Y., Panzara M.,A., and Davar, G., PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosis, J. Interferon Cytokine Res, 2010, vol. 30, no. 10, pp. 777–785.
12. Pepinsky, R.B., Lepage, D.J., Gill, A., Chakraborty, A., Vaidyanathan, S., Green, M., Baker, D.P., Whalley, E., Hochman, P.S., and Martin, P., Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-la with preserved in vitro bioactivity, J. Pharmacol. Exper. Therapeutics, 2001, vol. 297, no. 3, pp. 1059–1066.
13. Basu, A., Yang, K., Wang, M., Liu, S., Chintala, R., Palm, T., Zhao, H., Peng, P., Wu, D., Zhang, Z., Hua, H., Hsieh, M.C., Zhou, J., Petti, G., Li, X., Lanjua, A., Mendez, M., Liu, J., Longley, C., Mehlig, M., Borowski, V., Visanathan, M., and Filpula, D., Structure–function engineering of interferon beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation, Bioconjug. Chem., 2006, vol. 17, pp. 618–630.
14. Kurfurst, M.M., Detection and molecular weight determination of polyethylene glycol-modified hirudin by staining after sodium dodecyl sulfate-polyacrylamide gel electrophoresis, Anal. Biochem., 1992, vol. 200, pp. 244–248.
15. PEGfilgrastim: https://ms/usp.org/onographs/pegfilgrastim-1-0
16. Kinstler, O.B., Characterization and stability of N-terminally PFee EGylated rhG-CSF, Brems, D.N., Lauren, S.L., Paige, A.G., Hamburger, J.B., and Trenheit, M.J., Pharm. Res., 1996, vol. 13, pp. 996–1002.
17. Fee, C.J. and van Alstine, J.M., PEG-proteins: reaction engineering and separation issues, Chem. Engin. Sci., 2006, vol. 61, no. 3, pp. 924–939.
18. Clark, R., Olson, K., Fuh, G., Marian, M., Mortensen, D., Teshima, G., Chang, S., Chu, H., Mukku, V., Canova-Davis, E., Somers, T., Cronin, M., Winkler, M., and Wells, J.A., Long-acting growth hormones produced by conjugation with poly(ethylene glycol), J. Biol. Chem., 1996, vol. 271, no. 21, pp. 969–977.
19. Baker, D.P., Lin, E.Y., Lin, K., Pellegrini, M., Petter, R.C., Chen, L.L., Arduini, R.M., Brickelmaier, M., Wen, D., Hess, D.M., Chen, L., Grant, D., Whitty, A., Gill, A., Lindner, D.J., and Pepinsky, R.B., N-terminally PEGylated human interferon-beta-la with improved pharmacokinetic properties and in vitro efficacy in a melanoma angiogenesis model, Bioconjugation Chem., 2006, vol. 17, no. 1, pp. 179–188.
20. Caserman, S., Kusterle, M., Kunstelj, M., Milunovic, T., Shiefermeier, M., Jevsevar, S., and Porekar, V.G., Correlations between in vitro potency of polyethyleneglycol–protein conjugates and their chromatographic behavior, Anal. Biochem., 2009, vol. 389, pp. 27–31.
21. Wang, Y.S., Youngster, S., Grace, M., Bausch, J., Bordens, R., and Wuss, D.F., Structural and biological characterization of PEGylated recombinant interferon alpha-2b and its therapeutic implications, Adv. Drug Delivery Rev., 2002, vol. 54, no. 4, pp. 547–570.
22. Foser, S., Schacher, A., Weyer, K.A., Brugger, D., Dietel, E., Marti, S., and Schreitmuller, T., Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon-2a (PEGASYS), Protein Expression. Purification, 2003, vol. 30, pp. 78–87.